首页> 外文OA文献 >The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

【2h】

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

机译：EGFR T790M突变和BIM mRNA表达对欧尔替尼（EGFR-突变体NSCLC患者的结果）在随机分子III EURTAC试验中治疗EGFR-突变体NSCLC患者的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
Carlota Costa; Miguel Angel Molina; Ana Drozdowskyj; Ana Giménez-Capitán; Jordi Bertran-Alamillo; Niki Karachaliou; Radj Gervais; Bartomeu Massuti; Jia Wei; Teresa Moran; Margarita Majem; Enriqueta Felip; Enric Carcereny; Rosario Garcia-Campelo; Santiago Viteri; Miquel Taron; Mayumi Ono; Petros Giannikopoulos; Trever Bivona; Rafael Rosell;
展开▼
作者单位

展开▼
年度 2014
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-Mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial [J] . CostaC., MolinaM.A., DrozdowskyjA., Clinical cancer research: an official journal of the American Association for Cancer Research . 2014,第7期

机译：Ⅲ期EURTAC随机试验中，厄洛替尼或化学疗法治疗的EGFR突变型NSCLC患者中EGFR T790M突变和BIM mRNA表达对预后的影响
2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): A multicentre, open-label, randomised phase 3 trial [J] . RosellR., CarcerenyE., GervaisR., The lancet oncology . 2012,第3期

机译：厄洛替尼与标准化疗作为欧洲晚期EGFR突变阳性非小细胞肺癌（EURTAC）患者的一线治疗：一项多中心，开放标签，随机3期试验
3. Quality of life (QoL) analyses from optimal (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC) [J] . ChenG., FengJ., ZhouC., Annals of oncology: official journal of the European Society for Medical Oncology . 2013,第6期

机译：生活质量（QoL）来自最优（CTONG-0802）的分析，该研究为晚期EGFR突变阳性非小细胞肺癌（NSCLC）患者一线厄洛替尼与化疗一线治疗的III期随机，开放标签研究
4. Recruitment, retention and compliance in randomized, phase III clinical trials involving obese patients diagnosed with type 2 Diabetes Mellitus with respect to weight loss practicum report. [D] . Mithani, Moez S. 2012

机译：涉及诊断为2型糖尿病的肥胖患者的有关减肥实践的随机III期临床试验中的招募，保留和依从性报告。
5. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment [O] . Christina Demuth, Anne Tranberg Madsen, Britta Weber, 2018

机译：EGFR中的T790M耐药性突变仅在厄洛替尼治疗的NSCLC患者的cfDNA中发现该患者在治疗前具有激活的EGFR突变
6. P2.01-102 Outcome of Patients with EGFR Exon 19 Mutation in a Phase III Randomized Trial Comparing Gefitinib to Gefitinib with Chemotherapy [O] . K. Prabhash, V. Noronha, V. Patil, 2019

机译：eGFR外显子19突变患者患者的结果，将吉替尼与化疗比较Gefitinib

The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial

著录项

相似文献

相关主题

期刊订阅